invIOs stands for innovative immuno-oncology. We have three projects in early stages. One project is in Phase 1, treating patients with our autologous and transient cell therapy to silence the checkpoint inhibitor cbl-b and activate the innate and adaptive immune system. Other projects are in pre-clinical (using the same platform involving TILs) and a small molecule focussing on cancer.